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SUMMARY 
Background: Antenatal corticosteroids (ACS) are established as an effective method of reducing preterm morbidity 
and mortality. At the Korle Bu Teaching Hospital (KBTH), a tertiary referral centre in Ghana, it is recommended 
that a course of ACS should be given to mothers before delivery between 24 weeks to 34 weeks gestation. 
Objectives: The study was performed primarily to determine the level of adherence to guidelines on administration 
of ACS. 
Methods: All babies with gestational ages up to 34 weeks admitted to the neonatal unit (NICU) during the period of 
the study were eligible for inclusion.  
Results: There were 214 eligible admissions during the study period, of which 93 babies (43%) were studied due to 
poor access to medical records. Dexamethasone was the only steroid used, and mothers of 65 (70%) of the 93 babies 
received at least one dose; 17 (18%) received only one dose, 35 (38%) - 2 doses, 9 (10%) – 3 doses, and 4 (4%) - 4 
doses.  
Conclusions: This study has shown a low uptake of antenatal corticosteroids, similar to other low-income and mid-
dle-income countries. To improve preterm survival and morbidity, there is an urgent need to increase the use of cor-
ticosteroids before preterm deliveries in Ghana and other low-income and middle-income countries. 
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Prematurity is recognised as a leading cause of neonatal 
morbidity and mortality.1 Liggins and Howie showed in 
1972 that administration of a single course of antenatal 
corticosteroid to women at risk of preterm delivery re-
sulted in a lower incidence and severity of respiratory 
distress syndrome, intraventricular haemorrhage and 
necrotising enterocolitis.2 Antenatal corticosteroids 
(ACS) are now established as an effective and relatively 
low-cost method of reducing preterm morbidity and 
mortality.3 It is therefore important to monitor uptake of 
ACS in preterm delivery. 
 
Antenatal steroids increase foetal surfactant production 
through accelerated development of type 2 pneumo-
cytes, and enhance the neonatal response to postnatal 
surfactant treatment.4 Their use appears to reduce neo-
natal mortality rate even when infants are born less than 
24 hours after the first dose has been given. Reduction 
in RDS is seen in infants born up to 7 days after the first 
dose; no reduction in neonatal death, RDS or cerebro-
ventricular haemorrhage is seen in infants delivered 
more than 7 days after treatment with antenatal cortico-
steroids.5  
 
This study was performed to determine the level of ad-
herence and the impediments to compliance with guide-
lines on administration of ACS. It is hoped that this 
knowledge will help improve adherence to the guide-
lines. Furthermore, to help disseminate improved stand-
ards of antenatal and neonatal care, the literature on use 
of antenatal corticosteroids in low-income and middle-
income countries has been reviewed.   
 
METHODS 
The study was based on the neonatal unit (NICU) at the 
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from January to March 2015 and from December 2015 
to January 2016. The interruption in the study was due 
to inconsistent availability of staff for prompt identifica-
tion of newly admitted babies and completion of ques-
tionnaires. When babies were recruited some days after 
admission, instead of immediately after admission, their 
mothers were more likely to have been discharged, and 
their case notes were then impossible to retrieve. This 
resulted in a significant number of otherwise eligible 
babies not being included in the audit. 
 
The details of all babies admitted to the NICU are rou-
tinely entered into a register which, for the purposes of 
this audit, was inspected on a daily basis. All babies 
with gestational ages of at most 34 weeks (by dates or 
examination) who had been admitted to NICU during 
the period of the study were eligible for inclusion in the 
study. It is standard practice in the NICU for all admit-
ted babies who were preterm by dates to be assessed by 
experienced doctors for gestational age using the Bal-
lard scoring system.6 Collection of information was 
standardised by the use of a questionnaire designed for 
the purpose. In the first phase, paediatric and obstetric 
residents attached to the NICU identified new admis-
sions and completed these questionnaires by interview-
ing mothers and by reviewing clinical notes of babies. 
They also attempted to retrieve and review case-notes of 
these mothers. In one case where data was unavailable 
from these sources, it was obtained verbally from moth-
er’s obstetrician. Due to difficulties with resident doc-
tors’ availability to collect data, the study was suspend-
ed until a dedicated research assistant was appointed to 
restart data collection in the second phase of the study. 
 
Audit standards were based on guidelines in the De-
partment of Obstetrics and Gynaecology manual, Korle-
Bu Teaching Hospital.  
 
The relevant guideline statement was: 
A course of ACS should be given to all mothers before 
delivery between 24 weeks to 34 weeks gestation unless 
the risk to the mother or foetus outweighs the benefit 
(chorioamnionitis, acute foetal distress, and acute mas-
sive Antepartum haemorrhage). The course is IM Dex-
amethasone 6mg 12hourly for 4 doses, or where availa-
ble, Betamethasone 12mg IM, repeated 24 hours later. 
 
The standards for the study were   
1. All mothers of preterm babies less than 34 
weeks gestation requiring steroids should have 
received ACS.  
2. All ACS administered should be documented. 
3. ACS should be given as IM dexamethasone 
6mg 12hourly for 4 doses or IM betamethasone 
12mg repeated 24 hours later. 
4. All patients who do not receive a full course 
should have acceptable documented reasons. 
 
RESULTS 
The study involved preterm babies admitted to the 
KBTH NICU with gestations up to 34 completed weeks, 
from January to March 2015 and from December 2105 
to Jan 2016. During these periods there were 214 eligi-
ble admissions, of which only 43% (93 babies) could be 
studied due to missing case notes. In the first phase, 52 
out of 165 eligible babies (32%) were recruited, and in 
the second phase, 41 out of eligible 49 babies (84%). 
 
There were 51 males (55%) and 42(45%) females. Fif-
ty-two babies (56% of the total) were delivered vaginal-
ly. Maturity by dates is shown in table 1. Ten percent of 
the infants were born before 28 weeks gestation, and 
87% between 28 and 34 weeks.  
 
Table 1 Maturity by dates (MBD) of infants in the study 
MBD Frequency Percentage 
24 - 27 weeks + 6 days 9 10 
28 – 30 weeks + 6 days 33 35 
31-34 weeks + 0 days 50 54 
Not entered *1 3 
Total 93 100 
*The maturity by assessment of this baby was 31 weeks 
 
Birth weights are shown in table 2. Fifty eight percent 
of infants were less than 1500g, and 41% weighed be-
tween 1500g and 2499g.  
 
Table 2  Birth weights of the 93 infants in the study 
Birth weight Number Percentage 
<1000g 9 10 
1000-1499g 45 48 
1500-1999g 29 31 
2000-2499g 9 10 
2500-3000g 1 1 
N 2 2 
Total  93 100 
 
The commonest indications for preterm delivery were 
premature rupture of membranes (22%), hypertensive 
disorders managed by induction of labour or caesarean 
section (22%), and spontaneous preterm labour (11%). 
Seventy babies (75% of the total) were delivered in 
KBTH, 20 (22%) in other facilities, and 3(3%) at home. 
Maternal ages are shown in table 3. Seven percent of the 
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Table 3 Maternal ages of infants in the study 
Age Frequency Percentage 
<18 years 3 3 
18-20 years 4 4 
21-25 years 11 12 
26-30 years 33 35 
31-35 years 15 16 
36-40 years 17 18 




Total 93 100 * 
* Rounded up from 98% 
 
Eight (9% of 93 audited) mothers had a previous pre-
term delivery. Sixty-five (70% of 93 audited) mothers 
received antenatal steroids. Dexamethasone was the 
steroid given in all 65 cases: 17(18% of 93) received 1 
dose, 35(38%) 2 doses, 9(10%) 3 doses, and 4(4%) re-
ceived 4 doses.  
 
At least 74% of those who received antenatal steroids 
had this documented in the mother’s clinical notes. It is 
possible that there were more because in some cases 
where antenatal corticosteroids were verbally reported 
to have been given, the mothers’ notes were not availa-
ble. Of those who received less than 4 doses, none had 
documented reasons as to why a full course of ANC was 
not given. However, in 20 instances when steroids were 
not given, on detailed review of maternal notes and dis-
cussion with obstetric colleagues – 6 arrived in second 
stage of labour, 5 required emergency caesarean section, 
1 was born just before arrival, 1 was a home delivery, 
and in 7 cases no reason was identified. Table 4 shows 
performance against the audit standards. 
 





At least one dose of ACS to 
eligible mothers  
100 70 
Full course of ACS given 100 4 
Documentation of any ACS 
given 
100 74 
Documentation of why full 




In this study, 70% of babies delivered between 24 and 
34 weeks gestation received at least one dose of antena-
tal dexamethasone. This was higher than the 52% ob-
tained in the WHO Multicountry Survey on Maternal 
and Newborn Health, performed in 29 countries and 
involving 7547 women who gave birth at 26-34 weeks’ 
gestation. 7  
Rates of antenatal corticosteroid use varied between 
countries (median 54%, range 16–91%; IQR 30–68%).7  
Our rate was also higher than that obtained in a study 
performed by Gwako G, 2012 in the Kenyatta National 
Hospital in Kenya, where 46% of mothers who deliv-
ered prior to 34 weeks received antenatal corticoster-
oids.8 Other middle-income countries with low antenatal 
steroid coverage, compared with this study, include 
Cameroon (10%), Brazil (4%) and Ecuador (35%).9 
Pattanittum P et al reported that 40% of women who 
delivered at less than 34 weeks gestation in 9 hospitals 
in 4 countries in South East Asia, received antenatal 
corticosteroids.10 In Malawi, in a study by Ahlsen et al 
in two hospitals in the capital, Lilongwe – one district 
and one tertiary, less than 10% of the babies studied 
received any antenatal corticosteroids.11 Comparing 
mothers who received a full course of steroids (4 doses 
of dexamethasone), we obtained 4% in this study; 
Gwafo et al reported 3% in Kenya8; and Ahlsen et al 4% 
in Malawi.11 Gwafo however inappropriately used the 
number exposed to antenatal steroids as the denomina-
tor for this calculation instead of using the entire study 
population of 206, which would have resulted in a lower 
figure of 1%. These results fall far short of our audit 
standards and the practice in high-income countries. 
Among those who received antenatal corticosteroids, 
most had their last injection after 28 weeks gestation 
(92%). This was similar to that observed by Pattanittum 
P et al in 2008.10 
 
The commonest reasons for preterm delivery in our 
study were spontaneous preterm labour, preterm prema-
ture rupture of membranes or hypertension among those 
who received prenatal steroids. A similar finding was 
obtained by Gwako G et al8 and Pattanittum et al. 10 
 
Dexamethasone versus betamethasone 
Two corticosteroids, dexamethasone and betame-
thasone, have been shown to be safe and effective in the 
management of preterm birth.4 Roberts et al, after a 
Cochrane review of 21 studies, concluded that both cor-
ticosteroids significantly reduced combined foetal and 
neonatal death, RDS and cerebroventricular haemor-
rhage.5 Betamethasone however results in a greater re-
duction in RDS while dexamethasone significantly in-
creased the incidence of puerperal sepsis.5 These find-
ings were not in support of an earlier trial by Jobe et al 
which demonstrated a decreased risk of death with be-
tamethasone but not dexamethasone.12   Lee et al also 
corroborated the findings by Jobe.13 The World Health 
Organisation (WHO) does not express a preference.14  
Dexamethasone is the antenatal corticosteroid common-
ly available in Ghana; the price for a 4mg ampoule 
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Betamethasone is currently unavailable in the Korle-Bu 
Teaching Hospital but was available in April 2016 at 
one private pharmacy at 73 Ghana cedis for a 2mg am-
poule; a course of Betamethasone (2 doses of 12mg) 
therefore cost 876 Ghana cedis, compared to about 6 
Ghana cedis for Dexamethasone. It is likely that Beta-
methasone may be obtained at a lower price if pur-
chased in bulk directly by the hospital. 
 
Benefit of ACS in absence of neonatal intensive care 
Regarding the widespread use of ACS, cautions have 
been raised by some studies. Azad et al, after a system-
atic review of 21 studies in high-income and middle-
income country hospitals, concluded that the observed 
reductions in neonatal mortality rates after antenatal 
corticosteroids were highly unlikely to be replicated in 
settings without level 2 neonatal care. They recom-
mended restriction of single-dose antenatal steroids to 
mothers at “33 weeks’ gestation or less, in preterm la-
bour, and with easy access to good quality, round-the 
clock level 2 care”.15 The American Academy of Paedi-
atrics stipulates that level 2 facilities should be capable 
of delivering continuous positive airway pressure and 
providing mechanical ventilation for up to 24 hours. 
They must also have equipment such as portable X-ray 
machines and blood gas analysers, as well as various 
personnel such as physicians, specialised nurses, respir-
atory therapists, radiology and laboratory technicians, 
who must be available at all times to manage emergen-
cies.16 The KBTH NICU is not quite up to level 2 but 
has level 3 responsibilities, such as the care of babies 
born at <32 weeks’ gestation, as well as those weighing 
less than 1500g. Azad’s concerns seem to have been 
borne out by the findings of Althabe et al (2015). They 
reported, in a trial in low and middle-income countries, 
that increased use of antenatal corticosteroids in low 
birth weight infants did not decrease neonatal mortality, 
and that for every 1000 women exposed to this strategy, 
an excess of 3.5 neonatal deaths occurred, and maternal 
infection seemed to increase.17 However, a significant 
weakness of this study was the use of low birth weight 
as a proxy for prematurity, which could result in inap-
propriate steroid exposure for many pregnancies.  
 
Multiple courses of ACS 
According to current American College of Obstetricians 
and Gynaecology guidelines (2011), a single rescue 
course of antenatal corticosteroids may be considered if 
the gestational age is less than 32 weeks+6 days and the 
initial course of antenatal steroids was given more than 
2 weeks prior and the woman is judged to be likely to 
give birth within the next week. Regularly scheduled 
repeat courses or more than two courses are not recom-
mended.18 
 
Prediction of imminent delivery 
Accurate prediction of preterm delivery is essential to 
ensure timely administration of antenatal corticoster-
oids. In a study by Gyamfi-Bannerman et al in 2016, the 
following features were considered indicative of a high 
probability of delivery: spontaneous rupture of mem-
branes; preterm labour with at least 3cm dilatation or 
75% cervical effacement; or any other indication for 
preterm delivery by induction or caesarean section.19 
Transvaginal ultrasound assessment for cervical length 
and funnelling is another means of predicting imminent 
preterm birth.  
 
Limitations of this study 
A limitation of this study is the relatively small study 
population caused by 1) difficulty in retrieving maternal 
clinical notes once the mothers were discharged 2) una-
vailability of some mothers to complete questionnaires 
and 3) incomplete filling of some of the questionnaires 
by doctors. These difficulties were later overcome by 
the use of dedicated data collection personnel who ex-
tracted data before maternal discharge. This change re-
sulted in a higher recruitment of eligible cases - 52 out 
of 165 (31.5%) in the first phase, and 41 out of 49 
(84%) with the help of a research assistant in the second 
phase. Babies who received antenatal steroids but were 
delivered after 34 weeks gestation were not included in 
this study. Also excluded were stillbirths and preterm 
infants who did not survive long enough to be admitted 
to NICU. 
 
Conclusion and Recommendations 
The use of antenatal corticosteroids in KBTH compares 
favourably with data from other low-income and mid-
dle-income countries but is far below acceptable levels. 
The limited data from referring facilities indicates even 
lower usage of antenatal corticosteroid, and this must be 
addressed by increasing awareness of health workers of 
the indications for the use of ACS.  This task is rendered 
more difficult by inaccurate dating of pregnancy due to 
lack of formal education and poor access to antenatal 
care. Improving the uptake of ACS is daunting enough 
but it is only part of the package of measures needed to 
achieve better neonatal outcomes.  For example, the full 
benefits of ACS may not be realised if the standards of 
neonatal intensive care are low. Training should be of-
fered to health workers on prediction of preterm deliv-
ery to help reduce instances where delivery does not 
occur after administration of steroids resulting in the 
need to consider multiple courses of ACS. 
 
To facilitate implementation of the WHO recommenda-
tion “that dexamethasone or betamethasone should be 
available in all maternity facilities and should be includ-
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routine documentation of steroid use should be made 
mandatory in order to facilitate regular audit; health 
facilities should strengthen their medical records de-
partments and employ research assistants to enable col-
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